2014
DOI: 10.1016/j.yrtph.2013.12.008
|View full text |Cite
|
Sign up to set email alerts
|

Current concepts on integrative safety assessment of active substances of botanical, mineral or chemical origin in homeopathic medicinal products within the European regulatory framework

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
11
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(11 citation statements)
references
References 9 publications
0
11
0
Order By: Relevance
“…Application of the TTC approach has also been proposed for, or extended to, the risk assessment of other types of substances. These include substances present in consumer products (Antignac et al, 2011;Blackburn et al, 2005;SCCS, SCHER and SCENIHR, 2012;SCCS NfG, 2016): micropollutants, drug residues, pesticide metabolites and other impurities in drinking water (Brüschweiler, 2010;EFSA, 2016;Houeto et al, 2012;Laabs et al, 2015;Melching-Kollmuß et al, 2010;Mons et al, 2013); genotoxic impurities in human pharmaceuticals (EMEA, 2006); herbal preparations (EMEA, 2008); homeopathic medicines (Buchholzer et al, 2014); and human pharmaceutical substances carried over in multiproduct manufacturing facilities (Bercu and Dolan, 2013;Stanard et al, 2015). It has also been used as a first-level screening tool to prioritize for review a large number of substances identified as needing an assessment under the Canadian Environmental Protection Act (Health Canada, 2016).…”
Section: Introductionmentioning
confidence: 99%
“…Application of the TTC approach has also been proposed for, or extended to, the risk assessment of other types of substances. These include substances present in consumer products (Antignac et al, 2011;Blackburn et al, 2005;SCCS, SCHER and SCENIHR, 2012;SCCS NfG, 2016): micropollutants, drug residues, pesticide metabolites and other impurities in drinking water (Brüschweiler, 2010;EFSA, 2016;Houeto et al, 2012;Laabs et al, 2015;Melching-Kollmuß et al, 2010;Mons et al, 2013); genotoxic impurities in human pharmaceuticals (EMEA, 2006); herbal preparations (EMEA, 2008); homeopathic medicines (Buchholzer et al, 2014); and human pharmaceutical substances carried over in multiproduct manufacturing facilities (Bercu and Dolan, 2013;Stanard et al, 2015). It has also been used as a first-level screening tool to prioritize for review a large number of substances identified as needing an assessment under the Canadian Environmental Protection Act (Health Canada, 2016).…”
Section: Introductionmentioning
confidence: 99%
“…AM medications are prepared from plants, minerals, animals, and from chemically defined substances according to Good Manufacturing Practice and national drug regulations; quality standards of raw materials and manufacturing methods are described in the Anthroposophic Pharmaceutical Codex [ 65 ]. Toxicologically relevant starting materials (e.g., aconite, cinnabar) are highly diluted according to safety requirements of European regulations [ 66 ]. The available evidence suggests that AM medications are generally well tolerated, with infrequent adverse reactions of mostly mild to moderate severity [ 67 , 68 ].…”
Section: Introductionmentioning
confidence: 99%
“…Toxicologically relevant starting materials (e.g., aconite and cinnabar) are highly diluted according to safety requirements of European regulations [83]. Adverse reactions to these MPs are infrequent and usually of mild to moderate severity; anaphylactic reactions occur but are very rare [40, 84, 85].…”
Section: Resultsmentioning
confidence: 99%